Suven Pharmaceuticals has announced the acquisition of a controlling stake in NJ Bio Inc., a Princeton-based CRDMO specialising in Antibody-Drug Conjugates (ADCs) and related emerging modalities. The investment, worth $64.4 million, aligns with Suven’s strategic vision of offering end-to-end solutions
Suven Pharmaceuticals has announced a strategic investment in Sapala Organics, a Hyderabad-based Contract Development and Manufacturing Organisation (CDMO) specialising in Oligo drugs and nucleic acid building blocks. The agreement is subject to regulatory approvals and conditions. Sapala Organics is a key
Suven Pharmaceuticals, has announced a merger with Cohance Lifesciences. The merger was announced on Thursday, and it is expected to conclude over the next 12-15 months, subject to shareholder and regulatory approvals. The combined entity will have three distinct business units –
Suven Pharmaceuticals is a Manufacturer/Innovator company operating in the pharmaceutical industry. Suven Life Sciences provides services to leading Global Life Science and Fine Chemical majors in the domains of Custom Synthesis, Process R&D, Scale up and Contract Manufacturing of intermediates,
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
